PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
PlushCare, a leading virtual healthcare platform, has announced a significant upgrade to its online Weight Loss Program, enabling greater access to GLP-1-based prescription treatments such as semaglutide through board-certified physicians. This development marks a critical milestone in the company's mission to provide affordable, clinically supervised weight management across the United States.
Accessible at https://plushcare.com/weight-loss/, the updated platform streamlines the process for eligible adults to consult with licensed physicians, receive lab work if necessary, and access customized treatment plans—all from the comfort of their homes.
'We're committed to making evidence-based weight loss solutions more accessible through modern telehealth,' said a PlushCare spokesperson. 'Our program is designed to connect people with experienced doctors who can evaluate eligibility for medications like GLP-1s and deliver a personalized plan that fits their health goals.'
Expanded Features for 2025
The revamped Weight Loss Program now includes: Nationwide Access to medical providers via secure telehealth appointments
to medical providers via secure telehealth appointments Eligibility Evaluation for FDA-approved medications, including semaglutide
for FDA-approved medications, including semaglutide Personalized Plans tailored to each user's metabolic profile
tailored to each user's metabolic profile Optional Lab Testing with integrated results for precision treatment
with integrated results for precision treatment Transparent Pricing with no insurance required
The platform is optimized for mobile and desktop users, offering a seamless experience from appointment scheduling to prescription delivery.
Addressing a Growing National Health Concern
According to the CDC, over 40% of U.S. adults struggle with obesity, with rising demand for effective clinical support. PlushCare's integrated virtual care model delivers a scalable solution that removes traditional geographic and scheduling barriers.
Patients can typically get started in under 15 minutes by completing an intake form and booking a same-day appointment with a licensed doctor. If clinically appropriate, a prescription is sent to their preferred pharmacy.
About PlushCare
PlushCare is a virtual primary care and mental health platform that connects patients with top U.S. medical professionals through its secure telehealth platform. With a commitment to quality care, convenience, and evidence-based treatment, PlushCare is redefining access to modern healthcare.
For more information, visit https://plushcare.com.
Media Contact:PlushCare Media Relations
Email: [email protected]
Website: https://plushcare.com
Address: 345 California Street, Suite 600, San Francisco, CA 94105, United States
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
Disgusting ‘BBL smell' side effect might make people reconsider getting popular surgery
Do you smell that? The Brazilian butt lift (BBL) surgery is a procedure that enhances the size and shape of someone's rear end through a fat transfer. It's often considered a dangerous procedure by experts since there's a possibility of death, infection and more. Advertisement BBL surgeries are popular but there is a gross side effect that many people don't realize patients can get. xartproduction – Not only is a BBL surgery risky — but there's one bizarre, rather gross, side effect that comes from it that might make potential patients reconsider getting it done. 'The BBL smell is real,' Dr. Eric Anderson from Chicago-based Impressions Face + Body told the Daily Mail. Advertisement This unexpected side effect is often described as a musty or sour smell, according to South Shore Plastic Surgery. The team of experts there said a smell is often expected for BBL patients after sweating or sitting for long periods. But there are a variety of other factors, like tissue death — which is a BBL complication — and unhygienic habits, that could cause someone with a BBL to have a smelly behind, according to Anderson. A rancid smell can come from a BBL surgery for a few reasons. deagreez – Advertisement If a patient was 'overfilled with fat during the procedure,' fat necrosis — which is when fatty tissue in the butt dies — can occur. As a result, a rancid smell can develop. 'When there is more fat in an area than the blood supply allows, the fat will die through a smelly process called fat necrosis, which can lead to infections that need antibiotics, hospitalizations, and even sepsis,' he told the outlet. Advertisement Another more obvious cause is that BBL patients might struggle cleaning their derrières. If patients leave any residual stool or urine on the skin — bacteria can grow, which will cause a stinky smell, according to South Shore Plastic Surgery. Cevre Hospital recommends that people with a BBL use gentle, fragrance-free wet wipes or a bidet to properly clean themselves after using the bathroom. While many potential risks come with getting a BBL, one woman revealed that she underwent two BBL surgeries because the first one 'died.' 'A lot of the fat that's re-injected into your buttocks actually dies — like 50% or sometimes more,' Scarlet Black said in a TikTok video. 'For [this BBL] we focused on lifting [my butt] up and putting volume in it.' Black doesn't seem to mind having to go under the knife twice for the same procedure because she apparently has spent $36,000 on plastic surgeries to achieve her dream body.
Yahoo
2 hours ago
- Yahoo
2 Stocks to Buy on the Dip and Hold for 10 Years
Novo Nordisk's shares look attractive after a terrible performance over the past 12 months. DexCom has significant room to grow in its core market, despite disappointing results last year. 10 stocks we like better than Novo Nordisk › One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but still appear to be excellent long-term investment opportunities. Two great examples today in the healthcare sector are Novo Nordisk (NYSE: NVO) and DexCom (NASDAQ: DXCM). Although these two corporations have encountered significant headwinds since last year, they could deliver market-beating returns to investors who initiate positions today and stick with them for at least a decade. Novo Nordisk is coming off clinical setbacks and unimpressive financial results, at least by its lofty standards. The stock has significantly underperformed the market over the trailing-12-month period. But after this beating, the company's shares look attractive. Here are several reasons why. First, although Novo Nordisk's eternal rival, Eli Lilly, appears to be taking the lead in the fast-growing weight management market, the former still has excellent prospects in this rapidly expanding therapeutic area. Novo Nordisk's Wegovy continues to grow its sales at a good clip, and the company is awaiting approval from the U.S. Food and Drug Administration for an oral formulation of this popular medicine. Further, Novo Nordisk has promising internally developed pipeline candidates, such as amycretin, which recently entered phase 3 studies. The Denmark-based drugmaker has also enhanced its pipeline in this area, thanks to licensing deals and acquisitions. Second, Novo Nordisk has been working on diversifying its lineup and currently has promising pipeline candidates outside of its core treatment areas of diabetes and obesity. Novo Nordisk is developing medicines for conditions including hemophilia, Parkinson's disease, sickle cell disease, Alzheimer's disease, and others. Third, after being southbound for the past 12 months, Novo Nordisk's shares look reasonably valued. The company's forward price-to-earnings ratio is 16.8, compared to the 16.3 average for the healthcare industry. Novo Nordisk's financial results over the past year have been terrific by industry standards, but not quite what the market expected. That may have justified the sell-off, but at current levels, the stock looks attractive. Finally, Novo Nordisk is a solid dividend-paying company. It has increased its annual dividend per share by almost 284% over the past decade, while offering a forward yield of 2.3%. That's not exceptional, but it's above the S&P 500 index's average of 1.3%. Novo Nordisk is well-positioned to bounce back and deliver strong returns in the next decade as it rides weight management (and other) tailwinds. DexCom is a leading diabetes-focused medical device company. It develops continuous glucose monitoring (CGM) systems that help diabetics with constant blood sugar level measurements. DexCom has been successful thanks to the increased adoption of this innovative technology. Unlike blood glucose meters that are manually operated, use pesky and painful fingersticks, and can only tell a person's sugar level at one point in time, CGM devices are constantly monitoring things and automatically make measurements as often as every five minutes. Rrevenue and earnings have grown rapidly over the past decade, but the company hit a speed bump last year when its top-line growth slowed considerably, partly due to higher-than-expected rebates in the U.S., resulting in lower revenue per patient. That said, these are short-term issues that do little to impact the company's long-term prospects. And on that front, there are still plenty of reasons to be excited about DexCom's future. Consider that the company has ample room to grow, even in the U.S., a country that enjoys higher CGM penetration than most others. However, as DexCom has consistently pointed out, the population of patients who use CGM continues to lag behind those who are eligible for third-party coverage -- in other words, many people could obtain the technology paid for by insurers but have not yet opted in. Further, there is a vast worldwide opportunity, since only a tiny percentage of the diabetics in the world use CGM technology. Though many are in countries where DexCom does not do business, the company has generally increased its addressable market by entering new geographies. In the next 10 years, expect the company to do the same while benefiting from greater insurance coverage for CGM -- third-party payers, including governments, have been more willing to foot the bill because of the technology's benefits. All that should lead to consistent revenue and earnings growth for the medical device specialist. The stock has crushed the market in the past decade using this formula. In my view, it is well-positioned to do the same through 2035. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends DexCom and Novo Nordisk and recommends the following options: long January 2027 $65 calls on DexCom and short January 2027 $75 calls on DexCom. The Motley Fool has a disclosure policy. 2 Stocks to Buy on the Dip and Hold for 10 Years was originally published by The Motley Fool
Time Business News
5 hours ago
- Time Business News
Brighten Your Skin Safely: Why Hydroquinone 4% Cream Remains the Gold Standard for Hyperpigmentation
In the world of skincare, achieving a flawless, even-toned complexion is often a top goal. Whether you're dealing with dark spots, melasma, age spots, or acne scars, hydroquinone cream 4 percent remains one of the most trusted and dermatologist-recommended treatments for fading hyperpigmentation. If you're looking to understand how it works, what results to expect, and where to buy hydroquinone 4% cream online, this in-depth guide is for you. What is Hydroquinone 4% Cream? Hydroquinone is a skin-lightening agent that works by inhibiting tyrosinase, an enzyme responsible for the production of melanin (the pigment that gives skin its color). At a concentration of 4%, it's considered the most effective over-the-counter strength for treating moderate to severe hyperpigmentation. Common skin concerns treated with hydroquinone 4% cream include: Melasma Age spots Post-inflammatory hyperpigmentation (PIH) Acne scarring Freckles and sunspots This strength is typically recommended for individuals who have previously used lighter concentrations (like 2%) and are looking for more dramatic, faster results. Benefits of Hydroquinone 4% Cream The advantages of using hydroquinone cream at 4% strength are clear and well-documented: Rapid Fading of Dark Spots: Noticeable improvement in 4–6 weeks of consistent use. Noticeable improvement in 4–6 weeks of consistent use. Evens Out Skin Tone: Helps reduce blotchiness and patchiness. Helps reduce blotchiness and patchiness. Minimal Downtime: Non-invasive and easy to apply at home. Non-invasive and easy to apply at home. Dermatologist Recommended: A top choice in skin clinics for decades. People often search for terms like 'hydroquinone 4 cream results' or 'hydroquinone 4 cream before and after pictures' to see real-life transformations. A consistent regimen, combined with sun protection, makes all the difference. How to Use Hydroquinone 4% Cream Correctly To ensure maximum benefits while avoiding irritation or side effects, follow these steps: Cleanse: Wash your face with a mild, non-irritating cleanser. Apply Thin Layer: Use a small amount of hydroquinone cream on the affected area only. Moisturize: Wait a few minutes and apply a hydrating, non-comedogenic moisturizer. Sunscreen is Non-Negotiable: Always use broad-spectrum SPF 30 or higher during the day. Use Once Daily: Usually applied at night, unless otherwise instructed by a healthcare provider. Avoid using with products that contain benzoyl peroxide, AHAs, or vitamin C initially, as they may cause irritation. Hydroquinone Cream 4% vs. Other Bleaching Creams Some people wonder whether 'hydroquinone bleaching cream' is safe or if they should opt for natural alternatives. While hydroquinone is technically a bleaching agent, it is FDA-approved and widely used in clinical dermatology. Compared to natural alternatives, hydroquinone: Works faster and more effectively Is supported by decades of clinical studies Targets pigment directly at the source (melanin production) It's important to follow usage instructions and take breaks (often 3 months on, 1 month off) to prevent overuse. Understanding Hydroquinone 4 Cream Price and Accessibility The hydroquinone 4 cream price can vary significantly depending on the brand and where you purchase it. In the U.S., prescription formulations may cost $60–$100 or more. Fortunately, you can buy hydroquinone online from trusted international pharmacies like OKDERMO at a much more affordable rate—without a prescription in many regions. This makes it easier to access professional-grade skincare without paying a premium or visiting a dermatologist. Where to Buy Hydroquinone 4 Cream Online Safely While some turn to large marketplaces and search 'hydroquinone 4 cream Amazon,' it's important to be cautious. Not all listings guarantee authenticity or proper storage. Buying from a specialty skincare provider like OKDERMO ensures: Pharmaceutical-grade product Proper packaging and shipping Trusted customer service and global delivery OKDERMO carries Melalite 4 Cream, a well-known brand that delivers powerful skin-lightening results using 4% hydroquinone. Before and After Expectations Seeing hydroquinone 4 cream before and after pictures can be highly motivating. Most users report visible changes within 4 to 6 weeks, with optimal results seen after 2 to 3 months of regular use. Note: Hydroquinone results are not immediate. It requires consistent application, sun protection, and patience. Once the desired skin tone is achieved, dermatologists typically recommend discontinuing use or switching to maintenance products to avoid over-depigmentation. Safety and Precautions While hydroquinone is safe for most users, it's important to use it correctly and monitor your skin's reaction: Do not use on broken or inflamed skin. Avoid long-term use without breaks. A 3-month cycle is often recommended. A 3-month cycle is often recommended. Consult a dermatologist if you experience severe redness, burning, or unusual pigmentation changes. Always do a patch test before applying it to larger areas. Final Thoughts If you're seeking a reliable and effective solution to dark spots and uneven skin tone, hydroquinone 4% cream stands out as the gold standard. Backed by decades of medical use and clinical evidence, it delivers visible results in a matter of weeks. Rather than risking unknown sellers or overpriced prescriptions, buy directly from a trusted source. OKDERMO's Melalite 4 Cream offers pharmaceutical-grade strength and proven outcomes at an affordable price—no prescription required. TIME BUSINESS NEWS
